VRCA verrica.com: Price-to-Projected Revenue Ratio

Verrica Pharmaceuticals Inc. - graphic logo of issuer VRCA

Verrica Pharmaceuticals (VRCA) previously faced liquidity shortages due to costs associated with expanding its distribution. The forward price-to-sales ratio reflects the current market valuation, where the current status is 2.30. Looking ahead, the company expects profits from the sale of its unique molluscum treatment, relying on stable, non-cyclical demand within the dermatology sector.

VRCA Verrica Pharmaceuticals Inc.: Forward Price to Sales in the range 07/04/2022 - 11/18/2026

Summary analytical data breakdowns for Verrica Pharmaceuticals Inc. (VRCA)

Fundamental company analysis:Verrica Pharmaceuticals Inc. (VRCA)
Product sample of verrica.com

The operational success of Verrica Pharmaceuticals (VRCA) depends on market adoption of its drugs, making the forward P/S ratio a key tool for valuing future sales relative to market capitalization. This chart allows for a comparison of buying pressure against tax risks and product certification delays, determining how resilient the current business valuation is to potential drawdowns amid fierce competition.